Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...
The candlelighting ceremony at the World AIDS Day commemorative event. (Photo: PIA Samar) An early World AIDS Day observance ...
Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...
Local political activists put their heads together after first case of infection confirmed in 18-month-old girl.
Zacks Investment Research on MSN
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback